Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | NOS1 | P29475 | 9/20 | 0.64 |
| ▸ | NOS3 | P29474 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilarginine SCHEMBL23099403 | 0.86 | NOS1 (0.69) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736698 | 0.86 | NOS2 (0.68) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736695 | 0.86 | NOS2 (0.68) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29364827 | 0.83 | NOS2 (0.64) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Acetic Acid SCHEMBL29386173 | 0.81 | NOS2 (0.68) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL43261 | 0.81 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30679324 | 0.81 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288993 | 0.81 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288835 | 0.81 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30577923 | 0.81 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | claimed |
| WO-2026099761-A1 | PEPTIDES | SALEM YAHYA AHMED (EG) | 2026-05-15 | — | — | WO | disclosed |
| EP-4734770-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006362-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| CN-115192564-B | Phenylalanine derivative, pharmaceutical composition and application thereof in tumor treatment | 四川大学华西医院 | 2023-11-17 | — | — | CN | disclosed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | disclosed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | NOS2 3/4885CYP2C19 1848/4885CYP1A2 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.